|Last Price$9.02||Day Change (%)-0.22%|
|Open Price$8.99||Day Change ($)-0.02|
|Day Range8.89–9.06||52-Week Range5.88–13.18|
As of Mon 6/27/2016 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.